Reig Jofre doubles the production capacity of its subsidiary in Sweden

BarcelonaReig Jofre has doubled the production capacity of its Swedish subsidiary, Bioglan, located in the city of Malmö. This action allows for the expansion of the Yggdrasil production line and "represents a key step in the global supply of an innovative therapy for patients with advanced Parkinson's disease," according to group sources. The plant specializes in semi-solid products for the pharmaceutical and medical technology industries.

The treatment coming out of the Swedish plant is based on the Nobel Prize-winning research of Professor Arvid Carlsson and provides continuous relief when oral medications cease to be effective, according to the company.

The Yggdrasil line arises from a project initiated in 2019, when Bioglan was selected to scale up production of an ice therapy for patients who no longer respond to oral medication. Administered directly into the small intestine, the treatment offers "stable and sustained symptomatic relief, significantly improving patients' quality of life."

Strategic partners also played a key role in the project's success. Stada and Britannia contributed their scientific and technical expertise throughout the construction process, demonstrating "the strength of international collaboration in bringing complex, patient-centered therapies to market."

According to Ignasi Biosca, CEO of Reig Jofre, "this project embodies a firm commitment to sustained growth based on innovation in both products and the technologies and infrastructure that make them possible." He added that this expansion "strengthens the group's industrial network, boosts the autonomy of the European productive fabric, and consolidates the mission of making healthcare more accessible with high-impact solutions."

Bioglan is part of Reig Jofre and acts as a center of excellence for the development and production of semi-solid products. It offers both development and manufacturing services for medicines and medical devices.